Pfizer, BioNTech vaccine tackles 3 troubling COVID-19 variants in lab study As vaccine efforts ramp up, payers gear up to combat members' hesitancy Johnson & Johnson runs into vaccine supply issues in Europe, threatening second-quarter delivery pledge: Reuters 4 of the biggest healthcare trends CVS Health says to watch in 2021 Eli Lilly, ramping up COVID-19 antibody production, bids goodbye to longtime manufacturing chief COVID-19 tracker: PhRMA appeals to Biden for IP protection; FDA approves at-home test kit UPDATED Coronavirus tracker: Kaiser Permanente launches vaccine education campaign Russia's Sputnik V nabs first Twitter-verified vaccine handle, but is it PR or propaganda? Providence posts $306M loss in 2020 after patient revenue takes hit from COVID-19 GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits Featured Story | By Eric Sagonowsky Vaccine doses are fanning out around the globe, but officials worry that surging coronavirus variants could make the immunization push less effective. Thanks to a new lab study, Pfizer and BioNTech have some good news for them. read more |
| |
|---|
|
Top Stories By Paige Minemyer As the COVID-19 vaccine rollout continues, payers are gearing up to play a key role in easing vaccine fears and hesitancy. read more By Eric Sagonowsky Johnson & Johnson execs have assured investors and officials that the company is "comfortable" hitting its vaccine delivery targets. But with its U.S. rollout underway, the pharma giant has run into some supply problems in Europe, Reuters reports. read more By Paige Minemyer The healthcare giant released its annual Health Trends Report on Tuesday, and the analysis projects 10 industry trends that are likely to define 2021 in healthcare. read more By Fraiser Kansteiner As Eli Lilly hustles to make 1 million doses of its COVID-19 antibody cocktail by midyear, the company's manufacturing chief is heading for the exit. Myles O’Neill will pass the mantle to Edgardo Hernandez, now SVP of global parenteral drug product and device manufacturing. Meanwhile, the company's top compliance exec will also retire, handing the baton to a Lilly insider. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale PhARMA has appealed to President Biden to oppose a push to suspend the TRIPS Agreement, which protects intellectual property. The FDA has approved the first at-home COVID-19 testing kit which does not require a prescription. And more. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Beth Snyder Bulik The Russian-developed Sputnik V coronavirus vaccine nabbed verified status from Twitter last week, immediately doubling down on its broadcasting wave of tweets, retweets and plenty of American-style attitude. But is the now-authenticated social media account a pharma influencer case study or a cautionary tale of disinformation? read more By Robert King Providence posted a $306 million operating loss in 2020 due to higher expenses and a drop in patient volume stemming from the pandemic. read more By Eric Sagonowsky GlaxoSmithKline managed to notch some wins during the pandemic-challenged year of 2020, but COVID-19 took its toll—not only on the British pharma's finances, but on CEO Emma Walmsley’s pay, too. read more |
